Keywords ebola

Guidance for Personal Protective Equipment (PPE)

CDC

1 October 2024

This guidance refers only to the following viral hemorrhagic fevers: Ebola, Marburg, Lassa, Crimean Congo Hemorrhagic Fever (CCHF), and the South American Hemorrhagic Fevers (i.e., those caused by Junin, Machupo, Chapare, Guanarito and Sabia viruses).

keywords: CCHF, Crimean-Congo, donning/doffing, ebola, Lassa, Marburg, outbreak, PPE, South American Hemorrhagic Fevers, VHF

Establishment and application of a surrogate model for human Ebola virus disease in BSL-2 laboratory

Virologica Sinica

29 March 2024

Yang W, et al.

Highlights

Recombinant vesicular stomatitis virus expressing Ebola virus glycoprotein is lethal in immunocompetent Syrian hamsters.
The pathogenicity of VSV-EBOV/GP is species-specific, age-related, gender-associated, and challenge route-dependent.
Syrian hamsters develop uveitis, multi-organ failure, and severe systemic diseases resembling symptoms of human EBOV patients.
The model is available for anti-EBOV antibody and vaccine evaluation under BSL-2 conditions.

keywords: drug screening, ebola, EBOV, pathogenicity, recombinant vesicular stromatitis virus, surrogate models, syrian hamsters, vaccine evaluation, VHF

Preparing for another Ebola Outbreak: The impact of viral inactivation methods on commonly measured biochemistry analytes in plasma and urine

Clinical Biochemistry

17 January 2024

Zhou J, et al.
Infectious specimens containing viruses like Ebola require sample manipulation to ensure the safety of laboratory staff, which may negatively impact biochemistry test results. We evaluated the impact of viral inactivation methods on 25 biochemistry analytes in plasma, and seven biochemistry analytes in urine.

keywords: analytes, ebola, plasma, urine, VHF, viral inactivation

Case fatality risk among individuals vaccinated with rVSVΔG-ZEBOV-GP: a retrospective cohort analysis of patients with confirmed Ebola virus disease in the Democratic Republic of the Congo

The Lancet

7 February 2024

Coulborn R, et al
Vaccination with the Ebola vaccine significantly lowered case fatality risk vs not vaccinated.

keywords: ebola, rVSVΔG-ZEBOV-GP, vaccine, VHF

12/11/2023: Lab Advisory: Clinical Testing Guidance for Patients with Suspected Viral Hemorrhagic Fevers

CDC / Laboratory Outreach Communication System (LOCS)

11 December 2023

While the risk of VHFs being brought into the US by travelers is very low, CDC recommends that clinical laboratories review the testing guidance in this article for ebolaviruses, marburgviruses, Crimean-Congo hemorrhagic fever virus, arenaviruses (Lassa, Lugo, and South American hemorrhagic fever viruses), and Nipah virus.

keywords: arenaviruses, Crimean-Congo, ebola, Marburg, Nipah virus, VHF

Guidance on Performing Routine Diagnostic Testing for Patients with Suspected VHFs or Other High-Consequence Disease

CDC

This guidance applies to viral hemorrhagic fevers caused by infections with:

Filoviruses (ebolaviruses and marburgviruses),
Arenaviruses [Lassa, Lujo, and South American hemorrhagic fever viruses (Guanarito virus, Sabia virus,
Junin virus, Chapare virus, Machupo virus)],
Rift Valley fever virus, and
Crimean Congo hemorrhagic fever virus.

keywords: ebola, laboratory testing, routine diagnostic testing, VHF

Uganda declares Ebola Virus Disease outbreak

WHO

20 September 2022

WHO declares outbreak in Uganda with a rare Ebola Sudan virus.

keywords: ebola, outbreak, sudan strain, VHF

MMWR Ebola Reports

CDC/MMWR

keywords: ebola

Infectious Substance Special Permits

US DOT

keywords: ebola, permits, transportation

Donning Biological PPE - Ebola Patients

University of Nebraska Medical Center

keywords: ebola, PPE

Resources with keywords: ebola